Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.78B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.60M
Average 1.11M
AGIO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Agios Pharmaceuticals, Inc.NASDAQ: AGIO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $15.54M rose 36.8% year over year, ahead of the +26.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 10.0% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Stock-based compensation amounted to 97.3% of revenue in FY2025, down 20.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +36.8% holds above the trailing-twelve-month pace of +26.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 52.55M USD
- Year-over-year change
- +22.7%
- 4-year CAGR
- -0.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.55M | +22.7% |
| FY2024 | 2024-12-31 | 42.85M | -4.3% |
| FY2023 | 2023-12-31 | 44.77M | -9.2% |
| FY2022 | 2022-12-31 | 49.3M | -7.9% |
| FY2021 | 2021-12-31 | 53.51M | — |
Stock-Based Compensation vs competitors
How AGIO compares with its peers on the latest reported figures
- AGIO's LTM Mar 2026 stock-based compensation of $56.73M is the 5th largest of the 7 companies compared; the peer median is $103.27M.
- Its year-over-year change of +26.2% is the 4th highest of 7, against a peer median of +32.5%.
- Stock-based compensation amounts to 85.9% of revenue for AGIO, versus a peer median of 13.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.83M | -11.3% | +5.5% | 21.3% | |
| LTM Jun 2026 | $140.13M | +135.8% | +38.3% | 22.7% | |
| LTM Jun 2026 | $121.89M | +50.0% | +23.9% | 13.0% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Mar 2026 | $56.73M | +26.2% | +2.2% | 85.9% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $50.54M | +76.5% | +154.3% | — |
| LTM Mar 2026 | $3.48M | -33.4% | — | 0.9% | |
| Peer median (excluding AGIO) | $103.27M | +32.5% | +23.9% | 13.0% | |
Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (356.51M) | (231.8M) | (352.09M) | 673.73M | (412.78M) |
| Depreciation & Amortization | 9.24M | 8.56M | 6.62M | 5.65M | 5.18M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 53.51M | 49.3M | 44.77M | 42.85M | 52.55M |
| Change in Working Capital | (36.82M) | (16.43M) | (19.06M) | (19.77M) | (33.04M) |
| Accounts Receivables | (4.38M) | (2.21M) | (604K) | (1.3M) | (6.47M) |
| Inventory | 0 | (8.49M) | (10.58M) | (8.54M) | (5.3M) |
| Accounts Payables | 1.86M | 3.44M | (8.73M) | 6.6M | 1.75M |
| Other Working Capital | (34.31M) | (9.17M) | 864K | (16.53M) | (23.02M) |
| Other Non-Cash Items | (76.74M) | (119.1M) | 23.69M | (1.09B) | 15.12M |
| Operating Cash Flow | (407.32M) | (309.48M) | (296.06M) | (389.84M) | (372.98M) |
| Capital Expenditures | (5.74M) | (4.88M) | (999K) | (1.69M) | (4.32M) |
| Acquisitions (Net) | 0 | 132.75M | 0 | 40K | 0 |
| Purchases of Investments | (1.38B) | (1.03B) | (417.93M) | (1.54B) | (641.76M) |
| Sales of Investments | 829.8M | 1.15B | 674.68M | 818.38M | 1.03B |
| Other Investing Activities | 1.8B | 0 | (16.18M) | 1.09B | (10M) |
| Investing Cash Flow | 1.25B | 243.26M | 239.58M | 363.44M | 377.18M |
| Debt Repayment | (578K) | (331K) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 2.68M | 5.43M | 14.44M | 8.68M |
| Common Stock Repurchased | (802.49M) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.3M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | (765.77M) | 2.35M | 5.43M | 14.44M | 8.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 75.69M | (63.87M) | (51.05M) | (11.96M) | 12.88M |
| Free Cash Flow | (413.06M) | (314.36M) | (297.06M) | (391.53M) | (377.29M) |
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.